🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

80+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 80 recruiting trials for “thrombotic-thrombocytopenic-purpura

EARLY_Phase 1RecruitingNCT06888960

Safety Study of CC312 in Autoimmune Disease Patients

🏥 CytoCares Inc📍 1 site📅 Started Nov 2024View details ↗
RecruitingNCT06727669

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

👨‍⚕️ Xiao-Hui Zhang, MD, Peking University Institute of Hematology, Peking University People's Hospital📍 5 sites📅 Started Nov 2024View details ↗
Phase 3RecruitingNCT06544499

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

🏥 argenx📍 94 sites📅 Started Oct 2024View details ↗
RecruitingNCT06919341

RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

🏥 Fundación Española de Hematología y Hemoterapía📍 36 sites📅 Started Sep 2024View details ↗
RecruitingNCT06817395

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

🏥 Massachusetts General Hospital📍 1 site📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06787989

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

🏥 iCell Gene Therapeutics📍 1 site📅 Started Aug 2024View details ↗
EARLY_Phase 1RecruitingNCT06337474

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

🏥 Changzhou No.2 People's Hospital📍 1 site📅 Started Aug 2024View details ↗
EARLY_Phase 1RecruitingNCT06519565

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

👨‍⚕️ Heng Mei, Ph.D&M.D, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 2 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06838962

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

👨‍⚕️ Lei Zhang, MD, Chinese Academy of Medical Science and Blood Disease Hospital📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT06479291

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

👨‍⚕️ Yunfeng Cheng, Shanghai Zhongshan Hospital📍 7 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06478537

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

👨‍⚕️ Tienan Zhu, M.D., Peking Union Medical College Hospital📍 1 site📅 Started Jun 2024View details ↗
Phase 2RecruitingNCT06658834

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jun 2024View details ↗
RecruitingNCT06441578

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

👨‍⚕️ Study Director, Takeda📍 1 site📅 Started May 2024View details ↗
NARecruitingNCT06479304

The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP

👨‍⚕️ Yunfeng Cheng, Shanghai Zhongshan Hospital📍 7 sites📅 Started Apr 2024View details ↗
NARecruitingNCT06479317

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

👨‍⚕️ Yunfeng Cheng, Shanghai Zhongshan Hospital📍 7 sites📅 Started Apr 2024View details ↗
Phase 2RecruitingNCT06281327

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

👨‍⚕️ Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Mar 2024View details ↗
Phase 1, PHASE2RecruitingNCT06352281

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

👨‍⚕️ Sanbin Wang, Doctor, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China📍 1 site📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06168851

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

👨‍⚕️ Lei Zhang, MD, Chinese Academy of Medical Science and Blood Disease Hospital📍 1 site📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT06094881

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

👨‍⚕️ Lei Zhang, MD, Chinese Academy of Medical Science and Blood Disease Hospital📍 1 site📅 Started Dec 2023View details ↗
NARecruitingNCT05694325

Biologic Characterization of Patients With ITP

👨‍⚕️ Elisa Lucchini, SC Ematologia ASUGI📍 5 sites📅 Started Nov 2023View details ↗
← PreviousPage 3 of 4Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →